120 related articles for article (PubMed ID: 36739222)
1. Validation of automated post-adjustments of HDR prostate brachytherapy treatment plans by quantitative measures and oncologist observer study.
Dohlmar F; Morén B; Sandborg M; Smedby Ö; Valdman A; Larsson T; Carlsson Tedgren Å
Brachytherapy; 2023; 22(3):407-415. PubMed ID: 36739222
[TBL] [Abstract][Full Text] [Related]
2. Assessment of HDR brachytherapy-replicating prostate radiotherapy planning for tomotherapy, cyberknife and VMAT.
de Chavez R; Grogan G; Hug B; Howe K; Grigg A; Waterhouse D; Lane J; Glyde A; Brown E; Bydder S; Pryor D; Hargrave C; Charles PH; Hellyer J; Ebert MA
Med Dosim; 2022 Spring; 47(1):61-69. PubMed ID: 34551879
[TBL] [Abstract][Full Text] [Related]
3. Technical note: Evaluation of a spatial optimization model for prostate high dose-rate brachytherapy in a clinical treatment planning system.
Morén B; Bokrantz R; Dohlmar F; Andersson B; Setterquist E; Larsson T; Tedgren ÅC
Med Phys; 2023 Feb; 50(2):688-693. PubMed ID: 36542400
[TBL] [Abstract][Full Text] [Related]
4. Dosimetric impact of inter-observer catheter reconstruction variability in ultrasound-based high-dose-rate prostate brachytherapy.
Nicolae A; Murgic J; Kruljac I; Dubnitzky L; D'Alimonte L; Lu L; Cumal A; Law N; Morton G; Loblaw A; Chung HT; Ravi A
Brachytherapy; 2018; 17(2):306-312. PubMed ID: 29239812
[TBL] [Abstract][Full Text] [Related]
5. Investigating the role of constrained CVT and CVT in HIPO inverse planning for HDR brachytherapy of prostate cancer.
Sachpazidis I; Hense J; Mavroidis P; Gainey M; Baltas D
Med Phys; 2019 Jul; 46(7):2955-2968. PubMed ID: 31055834
[TBL] [Abstract][Full Text] [Related]
6. Dosimetric comparison between treatment plans of patients treated with low-dose-rate vs. high-dose-rate interstitial prostate brachytherapy as monotherapy: Initial findings of a randomized clinical trial.
Major T; Polgár C; Jorgo K; Stelczer G; Ágoston P
Brachytherapy; 2017; 16(3):608-615. PubMed ID: 28325472
[TBL] [Abstract][Full Text] [Related]
7. Dosimetric evaluation of high-dose-rate interstitial brachytherapy boost treatments for localized prostate cancer.
Fröhlich G; Agoston P; Lövey J; Somogyi A; Fodor J; Polgár C; Major T
Strahlenther Onkol; 2010 Jul; 186(7):388-95. PubMed ID: 20582396
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of bi-objective treatment planning for high-dose-rate prostate brachytherapy-A retrospective observer study.
Maree SC; Luong NH; Kooreman ES; van Wieringen N; Bel A; Hinnen KA; Westerveld H; Pieters BR; Bosman PAN; Alderliesten T
Brachytherapy; 2019; 18(3):396-403. PubMed ID: 30718176
[TBL] [Abstract][Full Text] [Related]
9. Dosimetric evaluation of MRI-to-ultrasound automated image registration algorithms for prostate brachytherapy.
Shaaer A; Paudel M; Davidson M; Semple M; Nicolae A; Mendez LC; Chung H; Loblaw A; Tseng CL; Morton G; Ravi A
Brachytherapy; 2020; 19(5):599-606. PubMed ID: 32712028
[TBL] [Abstract][Full Text] [Related]
10. The influence of the dwell time deviation constraint (DTDC) parameter on dosimetry with IPSA optimisation for HDR prostate brachytherapy.
Smith RL; Panettieri V; Lancaster C; Mason N; Franich RD; Millar JL
Australas Phys Eng Sci Med; 2015 Mar; 38(1):55-61. PubMed ID: 25481387
[TBL] [Abstract][Full Text] [Related]
11. A gEUD-based inverse planning technique for HDR prostate brachytherapy: feasibility study.
Giantsoudi D; Baltas D; Karabis A; Mavroidis P; Zamboglou N; Tselis N; Shi C; Papanikolaou N
Med Phys; 2013 Apr; 40(4):041704. PubMed ID: 23556874
[TBL] [Abstract][Full Text] [Related]
12. Towards artificial intelligence-based automated treatment planning in clinical practice: A prospective study of the first clinical experiences in high-dose-rate prostate brachytherapy.
Barten DLJ; Pieters BR; Bouter A; van der Meer MC; Maree SC; Hinnen KA; Westerveld H; Bosman PAN; Alderliesten T; van Wieringen N; Bel A
Brachytherapy; 2023; 22(2):279-289. PubMed ID: 36635201
[TBL] [Abstract][Full Text] [Related]
13. Dosimetry analyses comparing high-dose-rate brachytherapy, administered as monotherapy for localized prostate cancer, with stereotactic body radiation therapy simulated using CyberKnife.
Fukuda S; Seo Y; Shiomi H; Yamada Y; Ogata T; Morimoto M; Konishi K; Yoshioka Y; Ogawa K
J Radiat Res; 2014 Nov; 55(6):1114-21. PubMed ID: 24957754
[TBL] [Abstract][Full Text] [Related]
14. Comparison of IPSA and HIPO inverse planning optimization algorithms for prostate HDR brachytherapy.
Panettieri V; Smith RL; Mason NJ; Millar JL
J Appl Clin Med Phys; 2014 Nov; 15(6):5055. PubMed ID: 25493531
[TBL] [Abstract][Full Text] [Related]
15. Intraoperative ultrasound-based planning can effectively replace postoperative CT-based planning for high-dose-rate brachytherapy for prostate cancer.
Batchelar DL; Chung HT; Loblaw A; Law N; Cisecki T; Morton GC
Brachytherapy; 2016; 15(4):399-405. PubMed ID: 27180126
[TBL] [Abstract][Full Text] [Related]
16. Dosimetric comparison of high-dose-rate brachytherapy and intensity-modulated radiation therapy as a boost to the prostate.
Hermesse J; Biver S; Jansen N; Lenaerts E; Nickers P
Int J Radiat Oncol Biol Phys; 2010 Jan; 76(1):269-76. PubMed ID: 19775833
[TBL] [Abstract][Full Text] [Related]
17. Catheter position prediction using deep-learning-based multi-atlas registration for high-dose rate prostate brachytherapy.
Lei Y; Wang T; Fu Y; Roper J; Jani AB; Liu T; Patel P; Yang X
Med Phys; 2021 Nov; 48(11):7261-7270. PubMed ID: 34480801
[TBL] [Abstract][Full Text] [Related]
18. Adaptation of the CVT algorithm for catheter optimization in high dose rate brachytherapy.
Poulin E; Fekete CA; Létourneau M; Fenster A; Pouliot J; Beaulieu L
Med Phys; 2013 Nov; 40(11):111724. PubMed ID: 24320432
[TBL] [Abstract][Full Text] [Related]
19. Comparison of inverse planning simulated annealing and geometrical optimization for prostate high-dose-rate brachytherapy.
Hsu IC; Lessard E; Weinberg V; Pouliot J
Brachytherapy; 2004; 3(3):147-52. PubMed ID: 15533807
[TBL] [Abstract][Full Text] [Related]
20. Simultaneous needle catheter selection and dwell time optimization for preplanning of high-dose-rate brachytherapy of prostate cancer.
Wang C; Gonzalez Y; Shen C; Hrycushko B; Jia X
Phys Med Biol; 2021 Mar; 66(5):055028. PubMed ID: 33264753
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
